

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address CoMMISSI ORROOF PATENTS AND TRADEMARKS washington 10 20241 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO.
10 051,730	01 22/2002	William E. Julien	7235	8655
7	590 03 21 2003			
Paul M. Denk			EXAMINER	
763 South New St. Louis, MO			SAYALA, CHIIAYA D	
			ADTIVIT	DADLD NUMBED
		1761		
			DATE MAILED: 03/21/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

* ** *** *** *** *** ***

		Application No.	Applicant(s)				
Office Action Summary		10/051,730	JULIEN, WILLIAM E.				
		Examiner	Art Unit				
		C. SAYALA	1761				
Period fo	- The MAILING DATE of this communicat r Reply	ion appears on the cover sheet w	ith the correspondence address				
THE N - Exten after S - If the - If NO	DRTENED STATUTORY PERIOD FOR MAILING DATE OF THIS COMMUNICATION Susons of time may be available under the provisions of 37 (SIX 6) MONTHS from the mailing date of this communication period for reply specified above is less than thirty (30) daily period for reply is specified above, the maximum statutor e to reply within the set or extended period for reply will, the contraction of the period for reply will.	CFR 1 136(a) In no event, however, may a stron vs. a reply within the statutory minimum of thir vy period will apply and will expire SIX (6) MOI vy statute, cause the application to become A	reply be timely filed ty (30) days will be considered timely THS from the mailing date of this communication BANDONED (35 U.S.C. & 133)				
earne Status	d patent term adjustment See 37 CFR 1 704(b)		is the state of th				
1)	Responsive to communication(s) filed of	on .					
2a)□		☐ This action is non-final.					
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
· _	on of Claims						
	4) Claim(s) 1-13 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.							
	5) Claim(s) is/are allowed.						
	6)⊡ Claım(s) <u>1-13</u> is/are rejected.						
	Claim(s) is/are objected to.						
	Claim(s) are subject to restriction	and/or election requirement.					
	on Papers						
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
	nder 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).							
* S	ee the attached detailed Office action for	r a list of the certified copies not	received.				
	was the first complete and a second complete	······································	<i>x</i> :				
Attachment(s)							
1) Notice	of References Cited (PTO-892)	4) Interview	Summary (PTO-413) Paper Nois)				

Conservation and

Application/Control Number: 10/051,730

Art Unit: 1761

DETAILED ACTION

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rojections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

2. Claims 1-13 are rejected under 35 U.S.C. 102(b) as being by anticipated by Julien (US Patent 5709894).

See claims 1-10 which show all of the limitations. The product is the same as claimed herein except for the use terminology. A mere discovery of additional result in the use of the same old added materials in a composition cannot, of itself lend patentability to the claims. Besides, for composition claims, intended use of an otherwise old or obvious composition cannot render a claim patentable. In re Zierden, 162 USPQ 102, In re Jones, 50 USPQ 48, In re Spada, 15 USPQ 2d, 1655, In re Thuau 57 USPQ 324.

3. Claims 1-13 are rejected under 35 U.S.C. 102(b) as being by anticipated by Julien.

same as claimed herein except for the use terminology. A mere discovery of additional

Page 3

patentability to the claims. Besides, for composition claims, intended use of an otherwise old or obvious composition cannot render a claim patentable. In re Zierden, 102 USPQ 102, In re Jones, 50 USPQ 40, In re Spada, 15 USPQ 2d, 1055, In re Thuau 57 USPQ 324.

4. Claims 1-13 are rejected under 35 U.S.C. 102(b) as being by anticipated by Julien. (US Patent 5863574).

See col. 5, all the claims, col. 6, lines 15-20, col. 5, lines 35-45, col. 6, lines 45-51. The product is the same as claimed herein except for the use terminology. A mere discovery of additional result in the use of the same old added materials in a composition cannot, of itself lend patentability to the claims. Besides, for composition claims, intended use of an otherwise old or obvious composition cannot render a claim patentable. In re Zierden, 162 USPQ 102, In re Jones, 50 USPQ 48, In re Spada, 15 USPQ 2d, 1655, In re Thuau 57 USPQ 324.

5. Claims 1-4, 7,10-13 are rejected under 35 U.S.C. 102(b) as being by anticipated by Stuhr Enterprises. Inc. (WO 98/49903)

carrier of wheat middlings, uses a temperature as shown at page 9, and discloses a

Art Unit: 1761

moisture content between 1-10% (abstract). The product is the same as claimed herein except for the use terminology. A mere discovery of additional result in the use of the same old added materials in a composition cannot, of itself lend patentability to the ciaims. Besides, for composition claims, intended use of an otherwise old or obvious composition cannot render a claim patentable. In re Zierden, 162 USPQ 102, In re Jones, 50 USPQ 48, In re Spada, 15 USPQ 2d, 1655, In re Thuau 57 USPQ 324.

Double Patenting.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

6. Claims 1-13 are rejected under the judicially created doctrine of obviousnesstype double patenting as being unpatentable over claims 1-5 of U.S. Patent No.

distinct from each other because the feed additive is the same as the soil adjuvant.

Application/Control Number: 10/051,730 Page 5

Art Unit: 1761

7. Claims 1-13 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-7 of U.S. Patent No. C511521. Although the conflicting claims are not identical, they are not patentably distinct from each other because the feed additive is the same although the claims herein are drawn to a soil adjuvant.

- 8. Claims 1-13 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 5709894. Although the conflicting claims are not identical, they are not patentably distinct from each other because the reference feed additive is the same although the instant claims are of a different scope only to the extent of its use terminology.
- 9. Claims 1-13 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 5863574. Although the conflicting claims are not identical, they are not patentably distinct from each other because the feed additive is the same although the claim is of a different scope and the methods to feeding an animal overlap.
 - 10. Claims 1-13 are rejected under the judicially created doctrine of obviousness-

5/83238. Although the conflicting claims are not identical, they are not patentably

Application/Control Number: 10/051,730

Art Unit: 1761

Page 6

distinct from each other because the feed additive is the same although the claim is of a different scope and the methods to feeding an animal overlap.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to C. SAYALA at Group 1761, telephone number (703) 308-3035.

The fax phone number for the organization where this application or proceeding is assigned is (703) 305-3599.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is 703-308-0661.

C. SAYALA Primary Examiner Group 1700.